Semaglutide Injection Phase 2 Data Presented at ENDO Demonstra...
- Written by LATEST ASIANET NEWS RELEASES
- Category: Asia Net
CHICAGO, March 19, 2018 /PRNewswire-AsiaNet/ -- Oral session #12Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to 13.8% of their body weight after 52 weeks in a phase 2 trial, significantly more than those treated wit......





